Cargando…
Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum
The purpose of this analysis was to evaluate if serum levels of potential tumor markers for the diagnosis of malignant mesothelioma and lung cancer are affected by confounding factors in a surveillance cohort of workers formerly exposed to asbestos. SMRP, CA125, and CYFRA21-1 concentrations were det...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814766/ https://www.ncbi.nlm.nih.gov/pubmed/20130785 |
_version_ | 1782176994322022400 |
---|---|
author | Weber, Daniel Gilbert Johnen, Georg Taeger, Dirk Weber, Anne Gross, Isabelle Mercedes Pesch, Beate Kraus, Thomas Brüning, Thomas Gube, Monika |
author_facet | Weber, Daniel Gilbert Johnen, Georg Taeger, Dirk Weber, Anne Gross, Isabelle Mercedes Pesch, Beate Kraus, Thomas Brüning, Thomas Gube, Monika |
author_sort | Weber, Daniel Gilbert |
collection | PubMed |
description | The purpose of this analysis was to evaluate if serum levels of potential tumor markers for the diagnosis of malignant mesothelioma and lung cancer are affected by confounding factors in a surveillance cohort of workers formerly exposed to asbestos. SMRP, CA125, and CYFRA21-1 concentrations were determined in about 1,700 serum samples from 627 workers formerly exposed to asbestos. The impact of factors that could modify the concentrations of the tumor markers was examined with linear mixed models. SMRP values increased with age 1.02-fold (95% CI 1.01–1.03) and serum creatinine concentration 1.32-fold (95% CI 1.20–1.45). Levels differed by study centers and were higher after 40 years of asbestos exposure. CA125 levels increased with longer storage of the samples. CYFRA21-1 values correlated with age 1.02-fold (95% CI 1.01–1.02), serum creatinine 1.21-fold (95% CI 1.14–1.30) and varied by study centers due to differences in sample handling. Tumor marker concentrations are influenced by subject-related factors, sample handling, and storage. These factors need to be taken into account in screening routine. |
format | Text |
id | pubmed-2814766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-28147662010-02-03 Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum Weber, Daniel Gilbert Johnen, Georg Taeger, Dirk Weber, Anne Gross, Isabelle Mercedes Pesch, Beate Kraus, Thomas Brüning, Thomas Gube, Monika Biomark Insights Original Research The purpose of this analysis was to evaluate if serum levels of potential tumor markers for the diagnosis of malignant mesothelioma and lung cancer are affected by confounding factors in a surveillance cohort of workers formerly exposed to asbestos. SMRP, CA125, and CYFRA21-1 concentrations were determined in about 1,700 serum samples from 627 workers formerly exposed to asbestos. The impact of factors that could modify the concentrations of the tumor markers was examined with linear mixed models. SMRP values increased with age 1.02-fold (95% CI 1.01–1.03) and serum creatinine concentration 1.32-fold (95% CI 1.20–1.45). Levels differed by study centers and were higher after 40 years of asbestos exposure. CA125 levels increased with longer storage of the samples. CYFRA21-1 values correlated with age 1.02-fold (95% CI 1.01–1.02), serum creatinine 1.21-fold (95% CI 1.14–1.30) and varied by study centers due to differences in sample handling. Tumor marker concentrations are influenced by subject-related factors, sample handling, and storage. These factors need to be taken into account in screening routine. Libertas Academica 2010-01-28 /pmc/articles/PMC2814766/ /pubmed/20130785 Text en © 2010 The authors. http://creativecommons.org/licenses/by/2.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/2.0/). |
spellingShingle | Original Research Weber, Daniel Gilbert Johnen, Georg Taeger, Dirk Weber, Anne Gross, Isabelle Mercedes Pesch, Beate Kraus, Thomas Brüning, Thomas Gube, Monika Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
title | Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
title_full | Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
title_fullStr | Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
title_full_unstemmed | Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
title_short | Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
title_sort | assessment of confounding factors affecting the tumor markers smrp, ca125, and cyfra21-1 in serum |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814766/ https://www.ncbi.nlm.nih.gov/pubmed/20130785 |
work_keys_str_mv | AT weberdanielgilbert assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum AT johnengeorg assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum AT taegerdirk assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum AT weberanne assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum AT grossisabellemercedes assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum AT peschbeate assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum AT krausthomas assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum AT bruningthomas assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum AT gubemonika assessmentofconfoundingfactorsaffectingthetumormarkerssmrpca125andcyfra211inserum |